検索結果 - Ido Paz‐Priel

  • 検索結果 1 - 15 結果 / 15
結果の絞り込み
  1. 1
    C/EBPα Dysregulation in AML and ALL

    C/EBPα Dysregulation in AML and ALL 著者: Ido Paz‐Priel, Alan Friedman

    出版事項 2011
    全文の入手
    Revisão
    お気に入りに追加
    保存先:
  2. 2
    Cyclophosphamide for Rapid-Onset Obesity, Hypothalamic Dysfunction, Hypoventilation, and Autonomic Dysregulation Syndrome

    Cyclophosphamide for Rapid-Onset Obesity, Hypothalamic Dysfunction, Hypoventilation, and Autonomic Dysregulation Syndrome 著者: Ido Paz‐Priel, David W. Cooke, Allen Chen

    出版事項 2010
    全文の入手
    Artigo
    お気に入りに追加
    保存先:
  3. 3
    NF-κB p50 Regulates C/EBPα Expression and Inflammatory Cytokine-Induced Neutrophil Production

    NF-κB p50 Regulates C/EBPα Expression and Inflammatory Cytokine-Induced Neutrophil Production 著者: Dehua Wang, Ido Paz‐Priel, Alan D. Friedman

    出版事項 2009
    全文の入手
    Artigo
    お気に入りに追加
    保存先:
  4. 4
    Effects and Interferences of Emicizumab, a Humanised Bispecific Antibody Mimicking Activated Factor VIII Cofactor Function, on Coagulation Assays

    Effects and Interferences of Emicizumab, a Humanised Bispecific Antibody Mimicking Activated Factor VIII Cofactor Function, on Coagulation Assays 著者: Joanne I. Adamkewicz, David C. Chen, Ido Paz‐Priel

    出版事項 2019
    全文の入手 全文の入手
    Artigo
    お気に入りに追加
    保存先:
  5. 5
    Thromboembolic Events in Children and Young Adults With Pediatric Sarcoma

    Thromboembolic Events in Children and Young Adults With Pediatric Sarcoma 著者: Ido Paz‐Priel, Lauren Long, Lee J. Helman, Crystal L. Mackall, Alan S. Wayne

    出版事項 2007
    全文の入手
    Artigo
    お気に入りに追加
    保存先:
  6. 6
    CCAAT/Enhancer binding protein β controls androgen-deprivation-induced senescence in prostate cancer cells

    CCAAT/Enhancer binding protein β controls androgen-deprivation-induced senescence in prostate cancer cells 著者: David J. Barakat, Jian Zhang, Tiziano Barberi, Samuel R. Denmeade, Alan D. Friedman, Ido Paz‐Priel

    出版事項 2015
    全文の入手
    Artigo
    お気に入りに追加
    保存先:
  7. 7
    C/EBPα binds and activates the PU.1 distal enhancer to induce monocyte lineage commitment

    C/EBPα binds and activates the PU.1 distal enhancer to induce monocyte lineage commitment 著者: Christine Yeamans, Dehua Wang, Ido Paz‐Priel, Bruce E. Torbett, Daniel G. Tenen, Alan D. Friedman

    出版事項 2007
    全文の入手
    Artigo
    お気に入りに追加
    保存先:
  8. 8
    Improved Behavior and Neuropsychological Function in Children With ROHHAD After High-Dose Cyclophosphamide

    Improved Behavior and Neuropsychological Function in Children With ROHHAD After High-Dose Cyclophosphamide 著者: Lisa A. Jacobson, Shruti Rane, Lisa J. McReynolds, Diana Steppan, Allen Chen, Ido Paz‐Priel

    出版事項 2016
    全文の入手
    Artigo
    お気に入りに追加
    保存先:
  9. 9
    Immunogenicity of Emicizumab in People with Hemophilia A (PwHA): Results from the HAVEN 1-4 Studies

    Immunogenicity of Emicizumab in People with Hemophilia A (PwHA): Results from the HAVEN 1-4 Studies 著者: Ido Paz‐Priel, Tiffany Chang, Elina Asikanius, Sammy Chebon, Thomas Emrich, Elena Fernandez, Peter Kuebler, Christophe Schmitt

    出版事項 2018
    全文の入手
    Artigo
    お気に入りに追加
    保存先:
  10. 10
    Effect of emicizumab prophylaxis on bone and joint health markers in people with haemophilia A without factor VIII inhibitors in the HAVEN 3 study

    Effect of emicizumab prophylaxis on bone and joint health markers in people with haemophilia A without factor VIII inhibitors in the HAVEN 3 study 著者: Anna Kiialainen, Markus Niggli, Christine L. Kempton, Giancarlo Castaman, Tiffany Chang, Ido Paz‐Priel, Joanne I. Adamkewicz, Gallia G. Levy

    出版事項 2022
    全文の入手 全文の入手
    Artigo
    お気に入りに追加
    保存先:
  11. 11
    Low immunogenicity of emicizumab in persons with haemophilia A

    Low immunogenicity of emicizumab in persons with haemophilia A 著者: Christophe Schmitt, Thomas Emrich, Sammy Chebon, Elena Fernandez, Claire Petry, Koichiro Yoneyama, Anna Kiialainen, Monet Howard, Markus Niggli, Ido Paz‐Priel, Tiffany Chang

    出版事項 2021
    全文の入手 全文の入手
    Artigo
    お気に入りに追加
    保存先:
  12. 12
    The effect of emicizumab prophylaxis on long‐term, self‐reported physical health in persons with haemophilia A without factor VIII inhibitors in the HAVEN 3 and HAVEN 4 studies

    The effect of emicizumab prophylaxis on long‐term, self‐reported physical health in persons with haemophilia A without factor VIII inhibitors in the HAVEN 3 and HAVEN 4 studies 著者: Mark W. Skinner, Claude Négrier, Ido Paz‐Priel, Sammy Chebon, Víctor Jiménez‐Yuste, Michael U. Callaghan, Michaela Lehle, Markus Niggli, Johnny Mahlangu, Amy D. Shapiro, Midori Shima, Avrita Campinha‐Bacote, Gallia G. Levy, Johannes Oldenburg, Sylvia von Mackensen, Steven W. Pipe

    出版事項 2021
    全文の入手
    Artigo
    お気に入りに追加
    保存先:
  13. 13
    Emicizumab Prophylaxis in Patients Who Have Hemophilia A without Inhibitors

    Emicizumab Prophylaxis in Patients Who Have Hemophilia A without Inhibitors 著者: Johnny Mahlangu, Johannes Oldenburg, Ido Paz‐Priel, Claude Négrier, Markus Niggli, Maria Elisa Mancuso, Christophe Schmitt, Víctor Jiménez‐Yuste, Christine L. Kempton, Christophe Dhalluin, Michael U. Callaghan, Willem Buján, Midori Shima, Joanne I. Adamkewicz, Elina Asikanius, Gallia G. Levy, Rebecca Kruse‐Jarres

    出版事項 2018
    全文の入手 全文の入手
    Artigo
    お気に入りに追加
    保存先:
  14. 14
    Surgical outcomes in people with hemophilia A taking emicizumab prophylaxis: experience from the HAVEN 1-4 studies

    Surgical outcomes in people with hemophilia A taking emicizumab prophylaxis: experience from the HAVEN 1-4 studies 著者: Rebecca Kruse‐Jarres, Flora Peyvandi, Johannes Oldenburg, Tiffany Chang, Sammy Chebon, Michelle Y. Doral, Stacy E. Croteau, Thierry Lambert, Christine L. Kempton, Steven W. Pipe, Richard H. Ko, Benjamin Trzaskoma, Christophe Dhalluin, Nives Selak Bienz, Markus Niggli, Michaela Lehle, Ido Paz‐Priel, Guy Young, Víctor Jiménez‐Yuste

    出版事項 2022
    全文の入手 全文の入手
    Artigo
    お気に入りに追加
    保存先:
  15. 15
    Long-term outcomes with emicizumab prophylaxis for hemophilia A with or without FVIII inhibitors from the HAVEN 1-4 studies

    Long-term outcomes with emicizumab prophylaxis for hemophilia A with or without FVIII inhibitors from the HAVEN 1-4 studies 著者: Michael U. Callaghan, Claude Négrier, Ido Paz‐Priel, Tiffany Chang, Sammy Chebon, Michaela Lehle, Johnny Mahlangu, Guy Young, Rebecca Kruse‐Jarres, Maria Elisa Mancuso, Markus Niggli, Monet Howard, Nives Selak Bienz, Midori Shima, Víctor Jiménez‐Yuste, Christophe Schmitt, Elina Asikanius, Gallia G. Levy, Steven W. Pipe, Johannes Oldenburg

    出版事項 2020
    全文の入手 全文の入手
    Artigo
    お気に入りに追加
    保存先:

検索ツール: